Kawasaki disease in adults: observations in France and literature review Short title: Kawasaki disease in adults in France

Publication date: Available online 26 November 2015
Source:Autoimmunity Reviews
Author(s): Jean-Baptiste Fraison, Pascal Sève, Claire Dauphin, Alfred Mahr, Emeline Gomard-Mennesson, Loig Varron, Gregory Pugnet, Cédric Landron, Pascal Roblot, Eric Oziol, Gihane Chalhoub, Jean-Marc Galempoix, Sébastien Humbert, Philippe Humbert, Emilie Sbidian, Florent Grange, Olivier Bayrou, Pascal Cathebras, Philippe Morlat, Olivier Epaulard, Patricia Pavese, Thi Huong Du Boutin, Abdelkader Zoulim, Katia Stankovic, Hervé Bachelez, Amar Smail, C. Bachmeyer, Brigitte Granel, Jacques Serratrice, Graziella Brinchault, Arsène Mekinian, Nathalie Costedoat-Chalumeau, Anne Bourgarit-Durand, Xavier Puéchal, Loïc Guillevin, Maryam Piram, Isabelle Koné-Paut, Olivier Fain
ObjectiveKawasaki disease (KD) is a vasculitis that mostly occurs in young children and rarely in adults. We analyzed the characteristics of adult-onset KD (AKD) in France.MethodsWe collected retrospective and prospective data for patients with a diagnosis of KD occurring after the age of 18 years. Cases were obtained via various French medical networks and identified from the international literature.ResultsWe included 43 patients of AKD at 26 institution from 1992 to 2015, with mean (SD) age 30 (11) years (range 18–68) and sex ratio (M/F) 1.2; 34 patients met the American Heart Association criteria and 9 were incomplete AKD. The median time to diagnosis was 13 days (interquartile range 8–21). The main symptoms were fever (100%), exanthema (98%), changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical adenitis (55%) and cardiac abnormalities (45%). Overall, 35% of patients showed large-vessel vasculitis: coronary vasculitis (26%) and coronary aneurysm (19%). Treatment was mostly intravenous immunoglobulins (79%) and aspirin (81%). Four patients showed myocardial infarction due to coronary vasculitis, but none were treated with IVIg because of late diagnosis. After a median follow-up of 5 months (range 1–117), persistent aneurysm was noted in 9% of cases. Damage was significantly lower with early treatment than late or no treatment (p=0.01).ConclusionGiven the high frequency of cardiac involvement and complications in this series of AKD, diagnosis and treatment should not be delayed, and early IVIg treatment seems to improve the outcome.



from Allergy\Immunology via ola Kala on Inoreader http://ift.tt/1QLygv0
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via paythelady61 on Inoreader http://ift.tt/1XmcCBO
via IFTTT